mRNA stabilization focus gene therapy

Tumor cell selective stabilization of mRNA can control gene expression in viral vectors | By Tudor P Toma

Successful gene therapy treatment for cancer requires effective targeting of viruses that replicate only in tumor cells, but selective gene expression with adenoviral vectors has been difficult to achieve. Expression of various tumor-associated proteins is significantly enhanced in many tumors, partly by stabilization of their mRNAs through adenosine-uridine rich sequences in the 3′ untranslated regions (UTRs). In the June 8 advanced online publication Nature Biotechnology, Atique Ahmed and colleagues at the Mayo Clinic show that tumor cell selective stabilization of mRNA can be used to control therapeutic gene expression in cancer gene therapy viral vectors (Nature Biotechnology, DOI:10.1038/nbt835, June 8, 2003).

Ahmed et al. created a conditionally replication competent adenoviral vector in which expression of the essential E1A gene is regulated by ligation to the 3′UTR of PTGS2 (also known as COX2), allowing activated RAS/P-MAPK–specific stabilization of its mRNA. They observed that the Ad-E1A-COX virus is preferentially oncolytic in vitro in human tumor cells with high P-MAPK activity. In vivo, Ad-E1A-COX virus was at least as effective oncolytically as wildtype viruses in tumors expressing high levels of P-MAPK (U87 and U251), but it generated no significant therapeutic effects in tumors expressing low levels of P-MAPK (U118).

"To our knowledge a replicating (adeno)virus whose tumor selectivity is based upon control of gene expression at the level of mRNA stability has not been described previously. This strategy has great potential for expansion, because there are many different genes whose 3′ UTRs control selective mRNA stability under different physiological, pathological and tumor-associated conditions," conclude the authors.